Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03537508 · ClinicalTrials.gov registry record · Phase 3
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US
A Phase 3 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,627
- Enrollment target
NCT03537508 is a Phase 3 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 2,627 participants.
The verdict
NCT03537508, a Phase 3 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,627 participants
- Enrollment target
Study Summary
The purpose of this study was to compare the immunogenicity and describe the safety of MenACYW conjugate vaccine and MENVEO® when both are administered concomitantly with routine pediatric vaccines to healthy infants and toddlers in the US.
Interventions
- BIOLOGICAL MenACYW conjugate vaccine
- BIOLOGICAL MenACYW-135 conjugate vaccine
- BIOLOGICAL DTaP-IPV//Hib vaccine
- BIOLOGICAL Pneumococcal 13-valent conjugate vaccine
- BIOLOGICAL Pentavalent rotavirus vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,627 participants |
| Start Date | 2018-04-25 |
| Est. Completion | 2023-09-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03537508
The ClinicalTrials.gov registry entry for NCT03537508 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,627 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which MenACYW conjugate vaccine is the first listed.
NCT03537508 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03537508 about?
NCT03537508 is a clinical study titled "Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US". The purpose of this study was to compare the immunogenicity and describe the safety of MenACYW conjugate vaccine and MENVEO® when both are administered concomitantly with routine pediatric vaccines to healthy infants and toddlers in the US.
What is the current status of trial NCT03537508?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,627 participants. The study started on 2018-04-25. Estimated completion is 2023-09-22.
What interventions are being tested in trial NCT03537508?
The interventions under investigation include: MenACYW conjugate vaccine (BIOLOGICAL), MenACYW-135 conjugate vaccine (BIOLOGICAL), DTaP-IPV//Hib vaccine (BIOLOGICAL), Pneumococcal 13-valent conjugate vaccine (BIOLOGICAL), Pentavalent rotavirus vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03537508?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.